Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Panchali Roy Chowdhury"'
Autor:
Dr. Ed Clarke, MBChB, Yauba Saidu, MD, Jane U Adetifa, MD, Ikechukwu Adigweme, MBBS, Mariama Badjie Hydara, MBBS, Adedapo O Bashorun, MBBS, Ngozi Moneke-Anyanwoke, MBBS, Ama Umesi, MBBS, Elishia Roberts, BSc, Pa Modou Cham, BSc, Michael E Okoye, MBBS, Kevin E Brown, MBBS, Prof. Matthias Niedrig, PhD, Panchali Roy Chowdhury, MSc, Ralf Clemens, MD, Ananda S Bandyopadhyay, MBBS, Jenny Mueller, MD, David J Jeffries, PhD, Prof. Beate Kampmann, MD
Publikováno v:
The Lancet Global Health, Vol 4, Iss 8, Pp e534-e547 (2016)
Background: The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in the polio eradication endgame. This trial examined the safety and immunogenicity of IPV given alongside the measles–rubella and yellow fever vacci
Externí odkaz:
https://doaj.org/article/c846fb93745e477d99440ac938d34bdd
Autor:
Leonid Rumer, Elmara Graser, Timo Hillebrand, Thomas Talaska, Hans Dautel, Oleg Mediannikov, Panchali Roy-Chowdhury, Olga Sheshukova, Oliver Donoso Mantke, Matthias Niedrig
Publikováno v:
Emerging Infectious Diseases, Vol 17, Iss 2, Pp 325-326 (2011)
Externí odkaz:
https://doaj.org/article/49110708cb2541a1818d5a5d40575b47
Autor:
Christian Meier, Samba O. Sow, Panchali Roy Chowdhury, Abraham Hodgson, Prasad S. Kulkarni, Godwin Enwere, Brian D. Plikaytis, Hewad Laraway, Marie-Pierre Preziosi, Matthias Niedrig, Yuxiao Tang
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new menin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b227078c555d9c9eefc37cc619e905
https://doi.org/10.1093/cid/civ603
https://doi.org/10.1093/cid/civ603
Autor:
Ed Clarke, Matthias Niedrig, Ralf Clemens, Panchali Roy Chowdhury, David Jeffries, Ananda S Bandyopadhyay, Michael Okoye, Mariama Badjie Hydara, Ama Umesi, Beate Kampmann, Kevin E. Brown, Ikechukwu Adigweme, Elishia Roberts, Pa Modou Cham, Jenny Mueller, Jane U. Adetifa, Adedapo O Bashorun, Ngozi Moneke-Anyanwoke, Yauba Saidu
Publikováno v:
e547
e534
The Lancet Global Health, Vol 4, Iss 8, Pp e534-e547 (2016)
e534
The Lancet Global Health, Vol 4, Iss 8, Pp e534-e547 (2016)
Summary Background The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in the polio eradication endgame. This trial examined the safety and immunogenicity of IPV given alongside the measles–rubella and yellow feve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fec9a5a1afbb99ad74769153839a0ad3
http://hdl.handle.net/10044/1/34419
http://hdl.handle.net/10044/1/34419
